FAQ: HeartBeam Inc. Q2 2025 Results Conference Call and Business Updates

What is the purpose of HeartBeam Inc.’s conference call on August 13, 2025?

The conference call is to discuss HeartBeam Inc.’s second-quarter results for the period ended June 30, 2025, and provide updates on regulatory initiatives, commercial-readiness activities, and anticipated milestones.

Who will host the conference call for HeartBeam Inc.?

CEO Robert Eno and CFO Timothy Cruickshank will host the call, which will include a question-and-answer session.

How can I access the full press release about the conference call?

The full press release can be viewed at https://ibn.fm/9MZKX.

What is HeartBeam Inc.’s focus in the medical technology sector?

HeartBeam is dedicated to transforming cardiac care by providing powerful cardiac insights wherever the patient is, with its innovative cable-free 12-lead ECG technology designed for portable devices.

What makes HeartBeam Inc.’s technology unique?

HeartBeam is creating the first-ever cable-free 12-lead ECG capable of capturing the heart’s electrical signals from three dimensions, enabling actionable heart intelligence outside of medical facilities.

Where can I find more information about HeartBeam Inc.?

For more information, visit www.HeartBeam.com.

How can investors stay updated on HeartBeam Inc.’s latest news?

The latest news and updates relating to BEAT are available in the company’s newsroom at https://ibn.fm/BEAT.

What are the benefits of HeartBeam Inc.’s technology for cardiac care?

HeartBeam’s technology allows physicians to identify cardiac health trends and acute conditions outside of a medical facility, directing patients to appropriate care and redefining the future of cardiac health management.

How many patents does HeartBeam Inc. hold?

HeartBeam holds 13 U.S. and 4 international-issued patents related to its technology enablement.